Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC

Fast Track designation accelerates the path to US submission for the investigational monoclonal antibody in patients with recurrent or metastatic CLDN1-positive HNSCC Basel, Switzerland – 24 August 2023,  Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that the US Food and Drug Administration (FDA) has granted Fast Track development program for ALE.C04 for the treatment of patients with recurrent or metastatic, CLDN1-positive HNSCC.Fast Track designation aims to facilitate the development and expedite the review of new medicines that intend to treat serious or life-threatening conditions with unmet medical…

Continue ReadingAlentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC

ALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY

The trial confirms ALE.F02’s good safety profile, exposure and target biological activity Basel, Switzerland – 26 April 2023,  Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced results from the multiple-ascending dose (MAD) part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1 (CLDN1).The trial enrolled 24 subjects: 18 received the active drug and six received placebo across three dose levels. Participants were dosed every two weeks.Dr. Luigi Manenti, Chief Medical Officer at Alentis said: “This study is the first to target CLDN1 in humans. ALE.F02 showed good…

Continue ReadingALENTIS THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 MULTIPLE-ASCENDING DOSE COHORTS STUDY

ALENTIS TO PRESENT DATA AT AACR

CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors Basel, Switzerland, April 14, 2023 – Alentis Therapeutics, the Claudin-1 company, today announced that Alberto Toso, Alentis’ SVP Head of Oncology, will present at the American Association for Cancer Research Conference in Orlando, Florida on April 18th.The poster session entitled, CLAUDIN-1 targeting antibody ALE.C04 drives single agent activity and restores anti-PD1 efficacy in solid tumors, presents evidence that ALE.C04 is a highly specific humanized monoclonal antibody that recognizes a unique CLDN1-exposed epitope in different solid tumors.Non-Junctional Claudin-1 (NJ-CLDN1) is frequently overexpressed in solid tumors.…

Continue ReadingALENTIS TO PRESENT DATA AT AACR

ALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1

Basel, Switzerland – 13 April 2023, Alentis Therapeutics (“Alentis”), the Claudin-1 (CLDN1) company, is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, Alentis announced $105 million in Series C financing. The funding round was led by Jeito Capital together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.

Continue ReadingALENTIS THERAPEUTICS CLOSES $105 MILLION SERIES C FUNDING TO ADVANCE TRANSFORMATIONAL MEDICINES FOR CLAUDIN-1

Rare Disease Day 2023

Alentis ‘Shares Their Colors’ for ANCA-Associated Glomerulonephritis and Idiopathic Pulmonary Fibrosis Basel, Switzerland – 28 February 2023Rare Disease Day takes place annually on the last day of February to raise awareness for the more than 7,000 rare diseases and their impact on patients’ lives. Physicians, patients, patient advocates, researchers and medical & biotech companies from around the world shine a light on these little-known diseases and champion the need for education, research funding and access to treatment.Alentis has chosen to spread the word through a team event showing support for patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis and Idiopathic…

Continue ReadingRare Disease Day 2023

ALENTIS THERAPEUTICS makes key leadership appointments

Alentis names Markus Meyer COO and promotes Alberto Toso to SVP Head Oncology and Geoffrey Teixeira to SVP Head Fibrosis Basel, Switzerland – 17 February 2023 Alentis Therapeutics (“Alentis”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced the appointment of Markus Meyer to Chief Operations Officer (COO), Geoffrey Teixeira to SVP Head Fibrosis, Alberto Toso to SVP Head Oncology, effective 15 February.In his new role, Markus will be responsible for leading the development of Alentis’ portfolio of monoclonal antibodies that are highly selective in targeting exposed and non-junctional Claudin-1 (CLDN1). Alentis’ pipeline includes…

Continue ReadingALENTIS THERAPEUTICS makes key leadership appointments

Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1) F02 found to be well tolerated at all doses with a good safety profile and demonstrated initial evidence of on-target biological activity Planned initiation of first-in-human clinical study for lead oncology asset ALE.C04 in H2 2023 Basel, Switzerland – 9 January 2023 Alentis Therapeutics (“Alentis”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announces positive results from a single ascending dose Phase 1 study of its lead program, ALE.F02, currently in development for the treatment of advanced kidney,…

Continue ReadingPositive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1

Alentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer

Basel, Switzerland – 5 January 2023 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, today announced the appointment of Dr. Luigi Manenti as Chief Medical Officer (CMO).In his new role, Dr. Manenti will be responsible for leading the development of Alentis’s portfolio of monoclonal antibodies that are highly selective in targeting exposed and non-junctional Claudin-1 (CLDN1). Alentis’s pipeline includes ALE.F02, which is currently in Phase 1 clinical studies for the treatment of advanced kidney, liver and lung fibrosis; and ALE.C04, currently at IND submission stage to treat CLDN1+ solid…

Continue ReadingAlentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer

Preclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs

Important data provide further validation of Alentis’ approach to develop first-in-class anti-Claudin-1 monoclonal antibodies to treat advanced fibrosis and fibrotic cancersBasel, Switzerland – 21 December 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announces that Scientific Founder Professor Thomas Baumert’s team has published an article in the peer-reviewed journal Science Translational Medicine providing preclinical proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs.Severe tissue fibrosis is a key driver of end-stage organ failure and cancer, overall accounting for up to 45%…

Continue ReadingPreclinical data published in Science Translational Medicine provide proof-of-concept for Claudin-1-specific monoclonal antibodies for the treatment of fibrosis and cancer prevention across organs

Alentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model

Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target Claudin-1 to make solid tumors vulnerable to treatmentBasel, Switzerland, December 1, 2022 – Alentis Therapeutics, the Claudin-1 company, today announced that Alberto Toso, Head of Oncology, will present a poster at the ESMO Immuno-Oncology Congress in Geneva, Switzerland (and virtually), from 7-9 December 2022. The poster, CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform, presents evidence that non-junctional Claudin-1 is overexpressed in different solid tumors, drives T-cell exclusion and resistance to checkpoint inhibitors (CPI). Importantly, the use of non-junctional Claudin-1-targeting monoclonal antibody ALE.C04…

Continue ReadingAlentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model

End of content

No more pages to load